Neuroendocrine differentiation of prostate cancer is not systematically associated with increased 18f-fdg uptake

Matteo Bauckneht, Silvia Morbelli, Alberto Miceli, Sara Elena Rebuzzi, Giuseppe Fornarini

Research output: Contribution to journalArticlepeer-review

Abstract

Neuroendocrine differentiation (NED) of prostate cancer represents an acknowledged predictor of resistant and more aggressive disease. NED can be functionally exploited in vivo using PET/CT imaging with somatostatin analogs radiolabeled with 68Ga. Many previous reports have shown that 18F-FDG PET/CT should also be used in cases such as guiding management, as NED is systematically associated with increased glycolysis. We hereby discuss the case of a metastatic prostate cancer patient in which 68Ga-Dotatoc PET/CT revealed the occurrence of NED with low FDG-avidity.

Original languageEnglish
Article number468
JournalDiagnostics
Volume11
Issue number3
DOIs
Publication statusPublished - Mar 2021

Keywords

  • 18F-Fluorodeoxyglucose
  • 68Ga-Dotatoc
  • Metastatic castration-resistant prostate cancer
  • Neuroendocrine differentiation
  • Positron emission tomography

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Neuroendocrine differentiation of prostate cancer is not systematically associated with increased 18f-fdg uptake'. Together they form a unique fingerprint.

Cite this